Analyst firms · Morgan Stanley · EXEL
Morgan Stanley EXEL price target and rating history
Exelixis Inc. (EXEL) · Health Care
Morgan Stanley rates Exelixis Inc. (EXEL) Equal-Weight with a $48 price target, as of its latest action on Jan 8, 2026. It has published 3 rating actions on EXEL since July 2023, including 1 upgrade and 1 downgrade. Across 5 firms with a EXEL price target in the last 12 months, the median target is $52. Morgan Stanley's $48 is 8% below that.
- Current rating
- Equal-Weight
- Price target
- $48
- Median target, all firms
- $52
- Actions on EXEL
- 3
Morgan Stanley price target on EXEL
Every Morgan Stanley rating on EXEL
- Jan 8, 2026
- Jan 27, 2025
- Jul 11, 2023
How other firms rate EXEL
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BMO Capital Markets | Market Perform | $54 | Aug 19, 2026 |
| Leerink Partners | Market Perform | $52 | Aug 6, 2026 |
| Truist Securities | Hold | $54 | Jun 25, 2026 |
| Morgan Stanley | Equal-Weight | $48 | Jan 8, 2026 |
| BofA Securities | Underperform | $41 | Jan 5, 2026 |
| Wolfe Research | Peer Perform | Nov 18, 2025 |
Questions about Morgan Stanley and EXEL
- What is Morgan Stanley's price target for EXEL?
- Morgan Stanley's latest stated price target for Exelixis Inc. (EXEL) is $48, from its action on Jan 8, 2026.
- What is Morgan Stanley's rating on EXEL?
- Morgan Stanley rates EXEL Equal-Weight, a neutral rating, as of Jan 8, 2026.
- When did Morgan Stanley last change its view on EXEL?
- On Jan 8, 2026, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $48.
- How does Morgan Stanley's EXEL target compare with other analysts?
- Across 5 firms with a EXEL price target in the last 12 months, the median target is $52. Morgan Stanley's $48 is 8% below that.
More EXEL rating histories
All Morgan Stanley ratingsEXEL news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.